LIVE @ 1pm ET
Friday, September 4, 2026Â
AUTHORIZED. NECESSARY. BUT UNPAID?
The Inpatient Chemo Trap Hiding Inside Medicare Advantage
The inpatient stay is approved. The chemotherapy is medically necessary. But does that mean the drug is authorized—or that your hospital will actually be paid for it?
Friday, September 4, 2026
1:00 PM Eastern • 12:00 PM Central
Can't attend at 1 PM? Register anyway.
Registrants can watch the discussion on-demand after the live show.
Here's the problem...
A Medicare Advantage patient is hospitalized with spinal lymphoma causing neurologic compromise. The inpatient admission has been authorized.
Oncology says the patient needs inpatient chemotherapy. Medical necessity isn't really the question.
Then somebody asks:
And then comes the even more expensive question:
“Even if it's covered... WHO PAYS FOR IT?”
That real-world question appeared recently in the RAC Relief discussion group—and it exposed something much bigger than a single chemotherapy case.
Hospitals may be using the word “authorization” to describe three completely different questions:
1. COVERAGE
Is this treatment a covered, medically supported Medicare benefit for this patient and indication?
2. AUTHORIZATION
Does the Medicare Advantage plan require a separate approval for this particular drug or regimen—even though the inpatient stay is already approved?
3. PAYMENT
Is that expensive drug included in the hospital's inpatient payment—or does your MA contract provide a carve-out, stop-loss or some other separate reimbursement?
Covered does not automatically mean separately authorized.
Authorized does not automatically mean separately paid.
We're going to pull this apart LIVE Friday.
We'll use the actual inpatient chemotherapy case to examine what hospitals should do when clinical urgency, Medicare Advantage prior authorization, drug coverage, DRG payment and managed-care contracting collide.
We'll also tackle the new 2026 prior-authorization rules—including why the familiar 7-day / 72-hour rule should not simply be applied to a chemotherapy drug request—and we'll look at the separate timing rules that can apply to Part B drug determinations.
Then we'll ask another uncomfortable question:
WHAT EXACTLY DID THE PAYER AUTHORIZE?
And we'll discuss why an Original Medicare ABN isn't the easy fallback when a Medicare Advantage plan's payment is uncertain.
This discussion is especially important for:
Utilization Review • Physician Advisors • Revenue Integrity • Case Management • CDI • Coding • Pharmacy • Oncology Leadership • Managed Care Contracting • Denials & Appeals • Revenue Cycle Leadership
In fact, this may be one of those shows where you should gather several departments around the same screen—because no single department owns every part of this problem.
Join Us LIVE — or Register for the Recording
Friday, September 4 • 1:00 PM Eastern / 12:00 PM Central
Finally Friday! LIVE is FREE.
REGISTER FREE NOWCan't be there live? Register anyway for on-demand access.
And we'll leave you with something you can use Monday morning.
We'll build an Inpatient High-Cost Therapy Escalation Pathway during the show: who needs to be involved, which questions need answers before treatment, how to document payer communications, and how to separate the clinical decision from the reimbursement decision.
Because if nobody in your hospital can answer these questions at 4:35 Friday afternoon...
THAT is the problem we need to fix.
Finally Friday! Broadcast Sponsors
These companies are why you get these shows for FREE - they support our broadcasts financially.
Finally Friday! Broadcast Partners
These companies provide speakers and content for FREE - and are also why you get these shows for FREE. You should check our their products and services, too!
